CryoPort

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CryoPort achieves record revenue, eyes growth in cell therapy logistics

CryoPort's Q4 2022 performance reflects robust revenue growth and strategic investments, positioning the company for further expansion in cell and gene therapy logistics.
While facing challenges in manufacturing capacity and supply chain, CryoPort's focus on revenue diversification and margin improvement initiatives strengthens its competitive position.
The company's outlook for 2023 is optimistic, with opportunities in supporting commercial therapies, market share expansion, and new product launches driving growth.

CryoPort (CYRX) reports strong Q1 revenue growth and eyes global expansion

CryoPort's Q1 performance reflects robust revenue growth and strategic advancements in logistics solutions.
While facing industry challenges and capacity constraints, CryoPort is leveraging opportunities for expansion and innovation.
The company's focus on acquisitions, partnerships, and market growth positions it well for future success.
Investments in capabilities and global expansion underscore CryoPort's commitment to driving revenue and operational excellence.

CryoPort reports Q2 revenue impact from China, remains confident in growth

CryoPort faces challenges from China's economic conditions but remains confident in its long-term growth drivers in the cell and gene therapy industry.
Strategic investments in technology, premium product positioning, and operational enhancements are key strengths driving future growth and competitiveness.
Navigating short-term challenges, seizing expansion opportunities, and leveraging synergies with MVE in China are crucial for CryoPort's future success.

CryoPort reports robust Q3 earnings, eyes growth in life sciences

CryoPort's Q3 results met expectations, showcasing growth in revenue and execution of its corporate strategy for long-term profitability.
The company's performance reflects strong demand, strategic acquisitions, and a focus on innovation and customer service.
While facing challenges like manufacturing capacity and rising costs, CryoPort remains well-positioned to capitalize on market opportunities.
With a clear outlook for future growth and a stable financial position, CryoPort is poised for continued success in the life sciences industry.

CryoPort reports strong revenue, eyes cell therapy growth in 2024

CryoPort's FY 2023 performance driven by service revenue and global clinical trial support.
Focused on revenue growth in cell and gene therapy industry, introducing innovative products.
Addressing challenges in market competition, revenue trends, and debt management.
Positioned for progressive advancement in 2024, capitalizing on market opportunities.

Cryoport maintains revenue guidance amidst challenges, eyes growth opportunities

Cryoport maintains revenue guidance despite Q1 challenges, focusing on growth drivers and cost-saving measures for improved financial performance.
Strong cash balance, collaborations with logistics companies, and ongoing revenue growth initiatives position Cryoport for future success.
Challenges in MVE business and biologistics revenue softness require attention, but opportunities lie in financial improvement and revenue growth drivers.
Anticipation of continuous progression in the second half and positive integration with CRYOPDP highlight growth prospects for Cryoport.

CryoPort reports strong Q2 revenue growth, eyes profitability by 2025

CryoPort's Q2 2024 performance reflects robust revenue growth and cost-saving initiatives.
While facing challenges in soft demand and market conditions, the company eyes growth opportunities.
Confidence in revenue guidance and proactive measures signal a strategic path to profitability.
Strengthening commercial revenue and upcoming facility openings position CryoPort for future growth.

CryoPort reports Q3 growth, focuses on profitability and cost reduction

CryoPort's Q3 performance showcased growth in Life Sciences Services and strategic initiatives to drive profitability.
Despite challenges in the life sciences sector and uneven market recovery in MVE division, CryoPort remains focused on cost reduction and long-term growth.
Opportunities lie in new product launches, high-value contract acquisitions, and maintaining financial strength post-election.
Overall, CryoPort's resilience and strategic focus position the company for sustained growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

As a small logistic operator servicing other celllular therapy innovators, CryoPort is powered by the prudent merger/acquisition growth approach. Regardless of the bear market, CryoPort has been enjoying huge topline growth from successful acquisitions.

CryoPort: A Rare Investing Opportunity

Cryoport plans to establish an integrated supply chain platform with BioLife Plasma Services to offer standardized cell therapy collection, processing, and storage services in United States and Europe over time NASHVILLE, Tenn. , Sept. 8, 2022 /PRNewswire/ -- Cryoport, Inc.  (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced it has entered into a strategic relationship with BioLife Plasma Services, part of the global biopharmaceutical company Takeda, intended to provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies.

Cryoport Enters into Strategic Relationship with Takeda's BioLife Plasma Services

Cryoport, Inc. (NASDAQ:CYRX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Todd Fromer – Managing Partner-KCSA Jerrell Shelton – Chief Executive Officer Tom Heinzen – Vice President, Corporate Development and Investor Relations Robert Stefanovich – Chief Financial Officer Mark Sawicki – Chief Scientific Officer Conference Call Participants John Sourbeer – UBS Richard Baldry – Roth Capital Yuan Zhi – B. Riley Securities David Saxon – Needham & Co. David Larsen – BTIG Jacob Johnson – Stephens Operator Good afternoon.

Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q2 2022 Results - Earnings Call Transcript

The mean of analysts' price targets for CryoPort, Inc. (CYRX) points to a 36.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can CryoPort, Inc. (CYRX) Climb 36% to Reach the Level Wall Street Analysts Expect?

Record revenue of $64.2 million for the quarter, up 14% as reported and 18% at constant currency (year-over-year) Supporting a record 626 global clinical trials; a net of 17 new trials added during the quarter Opened first two Global Supply Chain Centers, which include BioServices, in June 2022 Expanded global footprint into Spain and Ireland NASHVILLE, Tenn. , Aug. 4, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and six-month periods ended June 30, 2022.

Cryoport Reports Results for the Second Quarter 2022

NASHVILLE, Tenn. , July 28, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended June 30, 2022 (second quarter 2022) on Thursday, August 4, 2022 after U.S. markets close.

Cryoport to Report Second Quarter 2022 Financial Results on August 4, 2022

Cryoport is not just any biotech company, as it is banking on the booming logistic businesses for the cell/gene therapy sector. Leveraging the powerful merger and acquisition approach, Cryoport has been enjoying leaping top-line growth year-over-year.

Cryoport: To Resume Aggressive Growth

Cryoport, Inc. (NASDAQ:CYRX ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Todd Fromer - President, KCSA Strategic Communications Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - CSO Conference Call Participants John Sourbeer - UBS Brandon Couillard - Jefferies Michael Jones - SVB Securities Joseph Conway - Needham & Co. Paul Knight - KeyBanc David Larsen - BTIG Yuan Zhi - B. Riley Securities Jacob Johnson - Stephens Operator Thank you for standing by.

Cryoport, Inc.'s (CYRX) CEO Jerrell Shelton on Q1 2022 Earnings Call Transcript

Revenue of $52.3 million Provides Full Year 2022 Revenue Guidance of $260-$265 million Expansion and advancement of robust clinical pipeline continues – now supporting a record 609 clinical trials, with Phase 3 clinical trials increasing from 69 to 81 year over year Cash and short-term investments of $600 million NASHVILLE, Tenn. , May 5, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three months ended March 31, 2022.

Cryoport Reports First Quarter 2022 Results

NASHVILLE, Tenn. , April 28, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended March 31, 2022 (first quarter 2022) on Thursday, May 5, 2022 after U.S. markets close.

Cryoport to Report First Quarter 2022 Financial Results on May 5, 2022

Acquisition of Cell&Co BioServices, Clermont-Ferrand, France, accelerates Company's EMEA expansion plans and development of its Global Supply Chain Network NASHVILLE, Tenn. , April 18, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it has acquired Cell&Co BioServices, headquartered in Clermont-Ferrand, France with additional operations in Pont-du-Château, France.

Cryoport Acquires Cell&Co BioServices

Being a logistics service provider for the booming cell/gene therapy sector, Cryoport is enjoying the robust industry tailwind and thereby positioning itself to be an investment bonanza. Various acquisitions like MVE Biological Solutions and CryoPDP are delivering leaping top-line growth for Cryoport.

Cryoport: An Industry Leader Basking In Industry Tailwinds

Cryoport has a history of success until recently, posting gains in revenue on its income statement for each of the last four years.

Cryoport: Risky Investment With Upside Potential

Company provides further update on financial impact of New Prague, MN fire NASHVILLE, Tenn., March 30, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that its New Prague facility has returned to full production.

Cryoport's MVE Biological Solutions' New Prague Manufacturing Plant Returns to Full Production

Management Presenting at Upcoming Investor Conferences NASHVILLE, Tenn., March 11, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has unanimously authorized a repurchase program, under which Cryoport may repurchase up to $100 million of its outstanding common stock and/or convertible senior notes.

Cryoport Authorizes $100 Million Repurchase Program

Cryoport, Inc.'s (CYRX) CEO Jerrell Shelton on Q4 2021 Results - Earnings Call Transcript

NASHVILLE, Tenn., Feb. 24, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three months and year ended December 31, 2021.

Cryoport Reports Fourth Quarter and Full Year 2021 Results

CryoPort, Inc. (CYRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why CryoPort, Inc. (CYRX) is Poised for a Turnaround After Losing 22.8% in 4 Weeks

CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CryoPort, Inc. (CYRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NASHVILLE, Tenn., Feb. 15, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2021 on Thursday, February 24, 2022 after U.S. markets close.

Cryoport Report's Fourth Quarter and 2021 Financial Results on February 24, 2022

NASHVILLE, Tenn., Feb. 9, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today provided an update on resumption of activities at the New Prague facility.

Cryoport Provides Positive Update on MVE Biological Solution's New Prague Facility

The stock price of CryoPort Inc (NASDAQ: CYRX) fell by 2.54% in the most recent trading session. This is why it happened.

CryoPort (CYRX) Stock: Why The Price Went Down

NASHVILLE, Tenn., Jan. 31, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today reports that on January 25, 2022, a fire occurred at the MVE Biological Solutions manufacturing facility located in New Prague, Minnesota.

Cryoport Reports Fire Damage at MVE's New Prague Facility

NASHVILLE, Tenn., Jan. 27, 2022 /PRNewswire/ --  Cryoport, Inc.  (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it has entered into a strategic partnership with Cell Matters, S.A.

Cryoport and Cell Matters Enter into Strategic Partnership

NASHVILLE, Tenn., Jan. 5, 2022 /PRNewswire/ -- Cryoport, Inc.  (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer and Robert Stefanovich, the Company's Chief Financial Officer will be presenting at the J.P.

News for CryoPort Stock (CYRX)